Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced on October 9, 2026, that it has entered into a co-education agreement with Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) to jointly educate physicians and prostate cancer centres on the complementary roles of PSMA-PET molecular imaging and Profound's MRI-guided TULSA-PRO® platform. The agreement is designed to expand urologist access for Profound and support more informed patient selection across the prostate care continuum. Investors may be watching this collaboration as a potential driver of broader market adoption for the TULSA Procedure™.

Key Points

  • Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) and Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) have entered a co-education agreement
  • The agreement establishes a framework to educate urologists, radiologists, and nuclear medicine physicians on integrating Telix's PSMA-PET imaging with Profound's TULSA-PRO® platform
  • Planned initiatives include medical society meetings, key opinion leader programs, educational summits, webinars, and clinical case study development
  • Investors should watch for updates on PSMA-PET–MR image-fusion capabilities planned for a future release of Profound's Treatment Delivery Console software

Scope of the Profound Medical and Telix Physician Education Initiative

The co-education agreement creates a structured framework for both companies to jointly engage urologists, radiologists, and nuclear medicine physicians across the United States and internationally. Planned activities include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs, and webinars. The collaboration will also involve development of educational content, clinical case studies, and best-practice materials centred on Telix's Gozellix® and Illuccix® PSMA-PET imaging technologies alongside Profound's TULSA-PRO® platform.

How PSMA-PET Imaging Could Expand TULSA-PRO's Patient Population

Profound's release states that PSMA-PET imaging may assist physicians in identifying distant metastases or disease beyond the prostate that could otherwise go undetected, enabling more precise patient stratification. The company believes this diagnostic capability could potentially broaden the population considered appropriate candidates for the TULSA Procedure™. The release also notes that approximately 85% of prostate cancers are multifocal, suggesting that more granular imaging data could meaningfully influence ablation planning decisions for a substantial share of patients.

PSMA-PET–MR Image-Fusion Feature Planned for Future TDC Software Release

Profound disclosed that it is developing PSMA-PET–MR image-fusion capabilities for inclusion in a planned future release of its Treatment Delivery Console software. The intended functionality would allow Telix's diagnostic PSMA-PET data to be incorporated directly into TULSA-PRO® treatment planning using real-time intra-operative MR images. Profound's release states this approach is designed to be more precise than competitor methods that rely on registering older diagnostic data to real-time ultrasound, representing a potential clinical and commercial differentiator for the platform.

Strategic Rationale for Profound's Collaboration with a Radiopharmaceutical Leader

The agreement provides Profound with increased access to urologists through Telix's established presence in the prostate cancer ecosystem. Telix's Illuccix® is commercially available in 22 countries, including the United States, giving the partnership meaningful international reach. Profound's release suggests the integration of PSMA-PET capabilities within TULSA-PRO® centres could strengthen their clinical and economic value proposition by supporting more informed treatment decisions. Financial terms of the co-education agreement were not disclosed in the announcement.